Drug Trial Radar · NCT07794670
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2028
Study completion May 2029
Sponsor
- Lead sponsor
- NewAmsterdam PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Conditions
- Preclinical Alzheimer's Disease
Interventions
Obicetrapib 10 mgDrug
once daily 10 mg Obicetrapib tablet
Matching placebo tabletsDrug
matching placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 52 in ptau 217Time frame: Baseline, Week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
K2 Medical Research
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.